Enveric Biosciences Inc., a biotechnology company focused on developing novel neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, has announced the filing of a new provisional patent application. This application pertains to a newly identified group of molecules with potential to address neurodegenerative diseases. According to Enveric, these molecules might offer therapeutic candidates for conditions such as Alzheimer's Disease by promoting BDNF signaling, a known therapeutic target in neurodegenerative diseases. A prototype molecule from this family has demonstrated promising pharmacokinetic characteristics in preliminary in vivo testing. Further investigation is planned to explore the therapeutic potential of these molecules.